Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 271

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 271
---
 |

The components of profit /(loss) before
tax and a reconciliation of the Company’s theoretical statutory tax benefit to income tax benefit is as follows:

|                                                                           |     | Year Ended   
 December 31, |   2024 |   |     |   |  2023 |   |
|:--------------------------------------------------------------------------|:----|:-------------|-------:|:--|:----|:--|------:|:--|
| Income (loss) before taxes                                                |     | $            | (4,801 | ) |     | $ | 4,132 |   |
| Israeli statutory income tax rate                                         |     |              |     23 | % |     |   |  23.0 | % |
| Theoretical statutory tax benefit (expense)                               |     |              | (1,104 | ) |     |   |   950 |   |
| Revaluation of convertible notes and warrants                             |     |              |    905 |   |     |   |  (464 | ) |
| Temporary deductible difference                                           |     |              |   (164 | ) |     |   |   (26 | ) |
| Profit (losses) for which a valuation allowance                           
 was provided or benefit from loss carryforwards and permanent differences |     |              |    363 |   |     |   |  (460 | ) |
| Income tax expense                                                        |     | $            |      - |   |     | $ |     - |   |

<div align='center'>F-21</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 9:- | COMMITMENTS AND CONTINGENCIES |

| 1. | Between September 2004 and December 2015, the Company received funding from the IIA for its participation                                 
 in certain research and development activities, based on budgets approved by the IIA, subject to the fulfillment of specified milestones. 
 The Company is committed to pay royalties to the IIA on proceeds from sale of products related to research and development activities     
 of which the IIA participates by way of grants. According to the funding terms, royalties between 3% and 4.5% are payable on sales        
 of developed products funded, up to 100% of the grant received by the Company, linked to U.S. dollar and bearing Term SOFR interest       
 rate. In the